Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

This study is testing whether two immunotherapy drugs — ipilimumab and nivolumab — given before surgery can improve outcomes for people with melanoma (skin cancer) that has come back and can potentially be removed surgically. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced melanoma (Stage IIIB–D or Stage IV) that has returned and is considered removable by a surgeon - Your recurrence was confirmed by a biopsy while receiving a specific type of immunotherapy (anti-PD-1 therapy) - You have acceptable organ function and performance status **You may NOT be eligible if...** - Your melanoma is in the eye (uveal melanoma) or originated in a mucous membrane - You have active autoimmune disease requiring treatment - You have received certain prior treatments that would conflict with the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.